Welcome to our dedicated page for Adaptive Biotechnologies news (Ticker: ADPT), a resource for investors and traders seeking the latest updates and insights on Adaptive Biotechnologies stock.
Adaptive Biotechnologies Corporation (Nasdaq: ADPT) is a commercial-stage biotechnology company that regularly issues news and regulatory updates related to its immune medicine platform, Minimal Residual Disease (MRD) business, and Immune Medicine programs. News about Adaptive Biotechnologies often highlights developments in its clonoSEQ MRD test, financial performance, scientific data presentations, and collaborations with biopharmaceutical partners.
Investors and clinicians following ADPT news can expect updates on MRD revenue trends, clonoSEQ testing volumes, and segment-level financial results, as reported in the company’s earnings press releases and accompanying Form 8-K filings. The company’s disclosures describe MRD as a key growth area, with clonoSEQ adoption and MRD revenue metrics frequently discussed in quarterly results and preliminary financial announcements.
Adaptive Biotechnologies also reports on scientific and medical conference activity, including presentations at meetings such as the American Society of Hematology (ASH) Annual Meeting. News coverage has described numerous abstracts featuring clonoSEQ data across multiple blood cancers, with a focus on how MRD assessment informs treatment decisions, evaluates depth of response, and supports clinical research in hematologic oncology.
In addition, ADPT news includes information on corporate and partnering events, such as participation in healthcare and investor conferences and agreements with pharmaceutical companies to use Adaptive’s immune medicine platform and immune receptor–antigen datasets. These items provide insight into how the company applies its technology in collaborations, target discovery efforts, and AI-enabled research. For ongoing context on Adaptive Biotechnologies’ MRD business, Immune Medicine initiatives, and regulatory disclosures, readers can review the continuing stream of press releases and SEC-referenced announcements associated with the ADPT symbol.
Adaptive Biotechnologies (Nasdaq: ADPT) has launched an enhanced clonoSEQ® B-cell Clonality (ID) report, which now includes immunoglobulin heavy chain (IgH) – V mutation status for chronic lymphocytic leukemia (CLL) patients. This report, the only FDA-cleared in vitro diagnostic for detecting and monitoring minimal residual disease (MRD) in CLL, offers dual insights from a single test. Including IGHV mutation status, which correlates with better outcomes, simplifies diagnosis and treatment planning for physicians. The update aims to enhance patient management by providing critical prognostic information at diagnosis.
Adaptive Biotechnologies has opened its new corporate headquarters and lab in Seattle, designed to foster growth and innovation in biotechnology. The 100,086 square foot facility features over 20,000 square feet of lab space to enhance its diagnostic pipeline and drug discovery efforts. With nearly double the workforce since the pandemic, Adaptive is committed to scaling operations. The company also launched a partnership with STEM Paths Innovation Network to support female students in STEM fields, demonstrating a commitment to diversifying the workforce.
Adaptive Biotechnologies (Nasdaq: ADPT) announced its upcoming presentation at IDWeek 2021, showcasing its immune medicine platform's capacity to differentiate between natural infections and vaccine responses related to SARS-CoV-2. New studies indicate that the T-cell response remains detectable nearly 12 months after positive PCR tests. The T-Detect™ COVID test, the first T-cell-based assay in the U.S., confirms prior infections through whole blood samples. The findings are significant for vaccine efficacy, diagnostics, and ongoing research into immune responses.
Adaptive Biotechnologies (Nasdaq: ADPT) announced its participation in the virtual Morgan Stanley Global Healthcare Conference on September 14, 2021, at 8:00 a.m. PT. The company will engage in a fireside chat, accessible via a live and archived webcast on their Investors webpage. Adaptive Biotechnologies focuses on leveraging the adaptive immune system to develop innovative clinical products for disease diagnosis and treatment. The company has three commercial products and a strong clinical pipeline addressing conditions like cancer and autoimmune diseases.
Adaptive Biotechnologies Corp. (Nasdaq: ADPT) and Curebase have partnered to enhance patient participation in clinical studies, focusing on Adaptive's T-Detect™ diagnostic test. The collaboration will initially target Lyme disease and COVID-19 patient data collection. With Curebase's decentralized trial model, studies can reach remote populations while preserving patient-provider relationships. The need for modernization in clinical trials is emphasized, particularly in increasing access for underrepresented patient groups.
Adaptive Biotechnologies has appointed Nitin Sood as the new chief commercial officer effective immediately. With over 15 years in the diagnostics and life sciences sectors, Sood's experience includes significant roles at Guardant Health and NuGEN. His appointment coincides with Adaptive's strategy for commercial growth and upcoming product launches, including immunoSEQ, clonoSEQ, and T-Detect. CEO Chad Robins emphasized Sood's proven ability to build and scale commercial organizations as vital for the company’s expansion plans.
Adaptive Biotechnologies reported financial results for Q2 2021, showcasing 83% revenue growth year-over-year, reaching $38.5 million. Sequencing revenue grew by 132% to $18.6 million, while development revenue rose 53% to $20 million. Despite this growth, the company faced an operating loss of $49.3 million, worsening from $33.5 million in Q2 2020. The company has $689.5 million in cash and expects to generate $148 million to $155 million in revenue for the full year 2021, indicating 54% growth at the midpoint.
Adaptive Biotechnologies (Nasdaq: ADPT) will release its financial results for Q2 2021 after market close on August 4, 2021. A conference call with management will follow at 1:30 PM PT/4:30 PM ET, accessible via their website. The company focuses on decoding the adaptive immune system to develop diagnostics and treatments for diseases, including cancer and autoimmune conditions. They boast three commercial products and a comprehensive clinical pipeline aimed at personalized immune-driven therapies.
Adaptive Biotechnologies announces the use of its immunoSEQ T-MAP COVID technology in a Nature study demonstrating T-cell immune response to the Johnson & Johnson COVID-19 vaccine against variants like B.1.351. The findings suggest preserved T-cell responses, even as neutralizing antibodies wane, indicating T-cells may offer essential protection from variants. The research underscores the importance of measuring T-cell responses in vaccine trials, especially against emerging strains.
Adaptive Biotechnologies (Nasdaq: ADPT) is set to present over 20 abstracts focusing on its clonoSEQ® Assay for assessing minimal residual disease (MRD) in blood cancers at the upcoming ASCO and EHA meetings. The clonoSEQ Assay is the first FDA-cleared test for MRD in chronic lymphocytic leukemia (CLL), multiple myeloma (MM), and B-cell acute lymphoblastic leukemia (B-ALL). The results emphasize its clinical relevance, particularly in monitoring treatment response and potential relapses.